IL111721A - Isoxazolines and isoxazoles and pharmaceutical compositions containing them - Google Patents

Isoxazolines and isoxazoles and pharmaceutical compositions containing them

Info

Publication number
IL111721A
IL111721A IL11172194A IL11172194A IL111721A IL 111721 A IL111721 A IL 111721A IL 11172194 A IL11172194 A IL 11172194A IL 11172194 A IL11172194 A IL 11172194A IL 111721 A IL111721 A IL 111721A
Authority
IL
Israel
Prior art keywords
isoxazoles
pharmaceutical compositions
compositions containing
isoxazolines
compounds
Prior art date
Application number
IL11172194A
Other languages
English (en)
Other versions
IL111721A0 (en
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL111721A0 publication Critical patent/IL111721A0/xx
Publication of IL111721A publication Critical patent/IL111721A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11172194A 1993-11-24 1994-11-21 Isoxazolines and isoxazoles and pharmaceutical compositions containing them IL111721A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15759893A 1993-11-24 1993-11-24
US23296194A 1994-04-22 1994-04-22
US33792094A 1994-11-10 1994-11-10

Publications (2)

Publication Number Publication Date
IL111721A0 IL111721A0 (en) 1995-01-24
IL111721A true IL111721A (en) 2000-06-01

Family

ID=27388036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11172194A IL111721A (en) 1993-11-24 1994-11-21 Isoxazolines and isoxazoles and pharmaceutical compositions containing them

Country Status (24)

Country Link
EP (2) EP0730590B1 (cs)
JP (1) JPH09505590A (cs)
KR (1) KR100359046B1 (cs)
AT (1) ATE198748T1 (cs)
AU (1) AU695853B2 (cs)
BR (1) BR9408137A (cs)
CA (1) CA2174838A1 (cs)
CZ (1) CZ141996A3 (cs)
DE (1) DE69426604T2 (cs)
DK (1) DK0730590T3 (cs)
ES (1) ES2154326T3 (cs)
FI (1) FI962184L (cs)
GR (1) GR3035610T3 (cs)
HR (1) HRP940952A2 (cs)
HU (1) HUT74690A (cs)
IL (1) IL111721A (cs)
NO (1) NO309768B1 (cs)
NZ (1) NZ276633A (cs)
PL (1) PL182303B1 (cs)
PT (1) PT730590E (cs)
RU (1) RU2149871C1 (cs)
SK (1) SK66696A3 (cs)
TW (1) TW483895B (cs)
WO (1) WO1995014683A1 (cs)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997011940A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
AU1335897A (en) * 1995-12-21 1997-07-17 Du Pont Merck Pharmaceutical Company, The Isoxazoline, isothiazoline and pyrazoline factor xa inhibitors
CA2240439A1 (en) * 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU2421797A (en) * 1996-03-15 1997-10-01 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
US6185453B1 (en) 1996-06-19 2001-02-06 Dupont Pharmaceuticals Company Iontophoretic delivery of integrin inhibitors
JP2000516230A (ja) * 1996-08-15 2000-12-05 デュポン ファーマシューティカルズ カンパニー Ｉｉｂ／ｉｉｉａ拮抗薬としての環状カルバメート類およびイソオキサゾリジン類
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
JP2002511052A (ja) * 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5738647A (en) 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
US5797867A (en) 1996-09-27 1998-08-25 Becton Dickinson And Company Iontophoretic drug delivery system, including method for activating same for attachment to patient
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
WO1998043962A1 (en) * 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
HRP980334A2 (en) * 1997-06-19 1999-04-30 Mimi Lifen Quan INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
ZA988735B (en) 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
US6136833A (en) * 1998-01-16 2000-10-24 Dupont Pharmaceuticals Company Pharmaceutical formulations and process for their preparation
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
WO2000000481A1 (en) * 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US6319937B1 (en) * 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
WO2000029406A2 (en) 1998-11-18 2000-05-25 Du Pont Pharmaceuticals Company Novel isoxazoline fibrinogen receptor antagonists
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
BR0010381A (pt) * 1999-03-11 2002-02-05 Du Pont Pharm Co Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
CN1378472A (zh) 1999-03-11 2002-11-06 杜邦药品公司 通过低分子量肝素与血小板聚集抑制剂间协同作用防治各种血栓栓塞疾病的联合治疗方法
CA2368630A1 (en) 1999-04-02 2000-10-12 Ruth R. Wexler Aryl sulfonyls as factor xa inhibitors
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US20030206906A1 (en) 2001-11-26 2003-11-06 Genentech, Inc. Catheter composition and uses thereof
RU2209070C1 (ru) * 2002-09-30 2003-07-27 Нестерук Владимир Викторович Способ получения лекарственного препарата для инъекций
EP1677783A2 (en) 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
US7414134B2 (en) 2004-10-12 2008-08-19 Amgen Inc. B1 bradykinin receptor antagonists
US7612060B2 (en) 2004-10-13 2009-11-03 Amgen Inc. Triazoles and methods of use
BRPI0617076B1 (pt) 2005-09-02 2021-07-06 Nissan Chemical Corporation Composto benzamida substituída por isoxazolina da fórmula (1) ou sal do mesmo; composto benzamida substituido por 4-hidroxiiminametila da fórmula (2) ou sal do mesmo; pesticida; agente agroquímico; parasiticida interno ou externo para mamíferos ou aves; inseticida ou acaricida
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
WO2007089335A2 (en) 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008070353A2 (en) 2006-11-07 2008-06-12 Genentech, Inc. Tissue plasminogen activator variant uses
UY32543A (es) 2009-04-07 2010-11-30 Astrazeneca Ab Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CN105636953B (zh) 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
EP4509511A1 (en) 2023-08-17 2025-02-19 Bayer Aktiengesellschaft Substituted spiro-isoxazolinyl lactams, salts thereof and their use as herbicidally active substances
CN117820143B (zh) * 2023-12-29 2026-06-02 上海应用技术大学 以kaiso蛋白为靶点的二苯醚类化合物及制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
FI934894L (fi) * 1991-05-07 1993-11-05 Merck & Co Inc Fibrinogenreceptorantagonister
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JP3240534B2 (ja) * 1992-06-05 2001-12-17 コニカ株式会社 画像形成方法

Also Published As

Publication number Publication date
NO309768B1 (no) 2001-03-26
TW483895B (en) 2002-04-21
HRP940952A2 (en) 1997-04-30
DE69426604T2 (de) 2001-05-10
GR3035610T3 (en) 2001-06-29
EP0970950A2 (en) 2000-01-12
AU1098095A (en) 1995-06-13
JPH09505590A (ja) 1997-06-03
KR960705794A (ko) 1996-11-08
PL182303B1 (en) 2001-12-31
AU695853B2 (en) 1998-08-27
KR100359046B1 (ko) 2003-08-02
EP0970950A3 (en) 2000-04-05
WO1995014683A1 (en) 1995-06-01
CA2174838A1 (en) 1995-06-01
CZ141996A3 (en) 1996-11-13
DE69426604D1 (de) 2001-02-22
DK0730590T3 (da) 2001-03-19
EP0730590B1 (en) 2001-01-17
ATE198748T1 (de) 2001-02-15
HU9601414D0 (en) 1996-07-29
FI962184A7 (fi) 1996-05-23
SK66696A3 (en) 1996-11-06
BR9408137A (pt) 1997-08-12
PT730590E (pt) 2001-05-31
PL314591A1 (en) 1996-09-16
HUT74690A (en) 1997-01-28
FI962184A0 (fi) 1996-05-23
NO962096D0 (no) 1996-05-23
IL111721A0 (en) 1995-01-24
RU2149871C1 (ru) 2000-05-27
EP0730590A1 (en) 1996-09-11
ES2154326T3 (es) 2001-04-01
NO962096L (no) 1996-05-23
FI962184L (fi) 1996-05-23
NZ276633A (en) 1998-04-27

Similar Documents

Publication Publication Date Title
IL111721A0 (en) Isoxazolines and isoxazoles and pharmaceutical compositions containing them
IL118262A0 (en) Isoxazolines and pharmaceutical compositions containing them
DK0730589T3 (da) Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister
IL99537A0 (en) Fibrinogen receptor antagonists and pharmaceutical compositions containing them
UA29416C2 (uk) Похідні 1,5 - бензодіазепіну, що є антагоністами гастрину та холецистокініну, спосіб їх одержання, фармацевтична композиція
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
MXPA05009103A (es) Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
IL103252A0 (en) Cyclic compounds and pharmaceutical compositions containing them
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
DK58291D0 (da) Krystalinsk stof og dets fremstilling
WO2000029406A3 (en) Novel isoxazoline fibrinogen receptor antagonists
WO2005035495A3 (en) Fibrinogen receptor antagonists and their use
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
BG105761A (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
IL99511A0 (en) Calcium uptake inhibitors
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
GB9412548D0 (en) Chemical compounds
BR9809742A (pt) Roxifiban cristalino, composição farmacêutica, método para inibir a aglutinação de uma proteìna, método para tratamento ou prevenção e distúrbios tromboembólicos e método para inibir a aglutinação de uma proteìna
AR013096A1 (es) Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed